14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
FMKT vs INKT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, MiNK Therapeutics, Inc. (INKT) is the stronger overall head-to-head candidate over The Free Markets ETF (FMKT) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). FMKT carries a Unified Composite Score of 44.7/100 (HOLD) at $19.88 (N/M Forward P/E, N/A operating margin), whereas INKT carries 42.8/100 (HOLD) at $8.02 (N/M Forward P/E, -5720.7% operating margin).
Composite vs. Pillar Nuance: While FMKT currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. INKT 42.8/100 HOLD), INKT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-5720.7% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
Technical & Structure Timing Caution: FMKT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.1); meanwhile INKT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FMKT vs INKT. Trailing 12-month operating profitability (FMKT N/A vs INKT -5720.7%) and valuation multiples (FMKT N/M vs INKT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $44.2M market capitalization and -5720.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ FMKT vs INKT Key Questions & Quantitative Answers
As of Nov 20, 2026, MiNK Therapeutics, Inc. (INKT) is the stronger overall head-to-head candidate over The Free Markets ETF (FMKT) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). FMKT carries a Unified Composite Score of 44.7/100 (HOLD) at $19.88 (N/M Forward P/E, N/A operating margin), whereas INKT carries 42.8/100 (HOLD) at $8.02 (N/M Forward P/E, -5720.7% operating margin). Composite vs. Pillar Nuance: While FMKT currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. INKT 42.8/100 HOLD), INKT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-5720.7% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: FMKT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.1); meanwhile INKT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
INKT leads the Growth & Scale pillar: FMKT posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with INKT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $200,000 TTM revenue (100.0% gross margin, -5720.7% operating margin). On trailing 12-month operating scale, FMKT generates N/A in USD-normalized revenue versus $200,000 for INKT. In operating R&D and SG&A reinvestment, FMKT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for INKT.
FMKT and INKT trade at balanced relative valuation multiples. FMKT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas INKT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FMKT (N/A ROE) versus INKT (-1239.0% ROE) capital efficiency.
In options market volatility and institutional positioning, FMKT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.91β · 16% Vol realized risk). By comparison, INKT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.